Astellas Highlights Breakthroughs in Oncology at 2024 ASCO Annual Meeting

Astellas Pharma Inc. will present new research from its innovative cancer therapies portfolio at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4. Sixteen abstracts will be showcased, including pivotal trial data supporting ongoing regulatory reviews. These presentations emphasize Astellas’ dedication to developing targeted treatments for hard-to-treat cancers such as prostate, urothelial, and gastric/gastroesophageal junction (GEJ) cancers.

Dr. Tadaaki Taniguchi, Chief Medical Officer of Astellas, highlighted the significance of the data, noting that recent regulatory successes are allowing their oncology medicines to reach more patients globally. Astellas remains committed to pursuing novel targets and enhancing patient survival and quality of life.

Astellas Presentations at 2024 ASCO Annual Meeting

Enfortumab Vedotin

Presentation TitleLead AuthorPresentation Details
Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancerD. PetrylakType: Oral Presentation
Abstract Number:
 4503
Date: June 3, 2024
8:00-11:00 AM CDT
Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)S. GuptaType: Oral Presentation
Abstract Number:
 4502
Date: June 3, 2024
8:00-11:00 AM CDT
Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202A. GiordanoType: Oral Presentation
Abstract Number: 1005
Date: June 1, 2024
3:00-6:00 PM CDT
Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously 
untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of cisplatin 
(cis)-eligible population from EV-302/KEYNOTE-A39
J. BedkeType: Poster Presentation
Abstract Number:
 4562
Date: June 2, 2024
9:00 AM-12:00 PM CDT
Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously 
untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin 
(cis)-ineligible population from EV-302/KEYNOTE-A39
M. Van Der HeijdenType: Poster Presentation
Abstract Number: 4563
Date: June 2, 2024
9:00 AM-12:00 PM CDT
Enfortumab vedotin (EV) in non-squamous and squamous non–small cell lung cancer (NSCLC) cohorts of EV-202K. MuroType: Poster Presentation
Abstract Number:
 8585
Date: June 3, 2024
1:30-4:30 PM CDT
Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202K. MuroType: Poster Presentation
Abstract Number: 4046
Date: June 1, 2024
1:30-4:30 PM CDT
Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC): 2-year event-free survival and safety data for Cohort HP. O’DonnellType: Poster Presentation
Abstract Number:
 4564
Date: June 2, 2024
9:00 AM-12:00 PM CDT
Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or 
metastatic head and neck squamous cell carcinoma: a cohort of the EV-202 trial
P. SwiecickiType: Poster Presentation
Abstract Number: TPS6116
Date: June 2, 2024
9:00 AM-12:00 PM CDT
Systematic Literature Review and Network Meta-Analysis of First-Line Therapies for Locally Advanced/Metastatic Urothelial CarcinomaL. BloudekType: Online publication
Abstract Number: e16547
Real-world first-line treatment patterns and outcomes in patients with locally advanced or metastatic urothelial carcinoma in the United StatesR. ChenType: Online Publication
Abstract Number: e23287


Enzalutamide

Presentation TitleLead AuthorPresentation Details
EMBARK post-hoc analysis of impact of treatment suspension (TxS) on health-related quality of life (HRQoL)S. FreedlandType: Oral Presentation
Abstract Number: 5005
Date: June 1, 2024
3:00-6:00PM CDT
EMBARK post hoc analysis of sexual activity (SA) patient-reported outcomes (PROs) in patients 
(pts) who were sexually active or interested in sex at baseline (BL)
S. FreedlandType: Poster Presentation
Abstract Number: 5084
Date: June 2, 2024
9:00 AM-12:00 PM CDT
Physicians use of first-line treatment intensification in metastatic castration-sensitive prostate cancer (mCSPC): A discrete choice experimentS. LoebType: Poster Presentation
Abstract Number: 5087
Date: June 2, 2024
9:00 AM-12:00 PM CDT
Characteristics and treatment (Tx) patterns (TxP) of high-risk biochemically recurrent (HR-BCR) non-metastatic castration-sensitive prostate cancer in the real-world by race, age, and prostate-specific antigen (PSA) doubling time (PSADT)A. MorgansType: Online-Only Abstract
Abstract Number: e17071


Zolbetuximab

Presentation TitleLead AuthorPresentation Details
Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinomaK. ShitaraType: Poster Presentation
Abstract Number: 4036
Date: June 1, 2024
1:30-4:30 PM CDT

Key presentations include:

  • Phase 3 EV-302 trial results on enfortumab vedotin combined with pembrolizumab versus chemotherapy in urothelial carcinoma.
  • Final overall survival results from the Phase 3 SPOTLIGHT study on zolbetuximab for gastric or GEJ adenocarcinoma.
  • Post-hoc analyses of the Phase 3 EMBARK trial evaluating enzalutamide for prostate cancer, including its impact on health-related quality of life and sexual activity.

Astellas will also present numerous studies and analyses on enfortumab vedotin and enzalutamide in various cancer types. The full schedule of Astellas’ presentations is available for review.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter